Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study.

ABSTRACT:

Background

Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). Six observational studies have reported CRC-specific survival outcomes in patients using aspirin after CRC diagnosis but the results from these studies have been conflicting. Using a population-based cohort design this study aimed to assess if low-dose aspirin use after diagnosis reduced CRC-specific mortality.

Methods

A cohort of 8391 patients with Dukes' A-C CRC (2009-2012) was identified from the Scottish Cancer Registry and linked to national prescribing and death records. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for CRC-specific mortality were calculated using time-dependent Cox regression.

Results

There were 1064 CRC-specific deaths after a median fo

SUBMITTER: Gray RT 

PROVIDER: S-EPMC6389196 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature